Probiotics as Antifungals in Mucosal Candidiasis

Clin Infect Dis. 2016 May 1;62(9):1143-53. doi: 10.1093/cid/ciw038. Epub 2016 Jan 29.

Abstract

Candidais an opportunistic pathogen that causes mucosal and deep systemic candidiasis. The emergence of drug resistance and the side effects of currently available antifungals have restricted their use as long-term prophylactic agents for candidal infections. Given this scenario, probiotics have been suggested as a useful alternative for the management of candidiasis. We analyzed the available data on the efficacy of probiotics in candidal colonization of host surfaces. A number of well-controlled studies indicate that probiotics, particularly lactobacilli, suppressCandidagrowth and biofilm development in vitro.A few clinical trials have also shown the beneficial effects of probiotics in reducing oral, vaginal, and enteric colonization byCandida; alleviation of clinical signs and symptoms; and, in some cases, reducing the incidence of invasive fungal infection in critically ill patients. Probiotics may serve in the future as a worthy ally in the battle against chronic mucosal candidal infections.

Keywords: Candida; Lactobacillus; candidiasis; probiotics.

Publication types

  • Review

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • Antifungal Agents / therapeutic use*
  • Candidiasis / microbiology
  • Candidiasis / prevention & control
  • Candidiasis / therapy*
  • Female
  • Humans
  • Infant
  • Infant, Newborn
  • Lactobacillus
  • Middle Aged
  • Probiotics / therapeutic use*
  • Young Adult

Substances

  • Antifungal Agents

Supplementary concepts

  • Systemic candidiasis